Drug intelligence / Profile preview

AqT-Tubulysin A

Development stage: Preclinical
Lead developer: AqueaTether Therapeutics
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intraperitoneal, Intravenous, Intramuscular, Subcutaneous, Parenteral, Spinal, Epidermal

Overview

AqT-Tubulysin A is a cytotoxic payload-linker conjugate developed by AqueaTether Therapeutics for the construction of antibody-drug conjugates (ADCs). It combines the potent antimitotic agent Tubulysin A with the proprietary AqueaTether (AqT) technology, which utilizes a hydrophilic tether to enhance the solubility and conjugation efficiency of hydrophobic payloads. Tubulysin A functions by inhibiting tubulin polymerization, leading to cell cycle arrest and apoptosis. This asset is part of a platform of 'AqT-drugs' intended for use in developing targeted cancer therapies through partnerships with biopharmaceutical companies.

Other names: Tubulysin A

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on AqT-Tubulysin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AqT-Tubulysin A.

Explore the full profile